Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
